Home › Research › Risk genes beyond APOE
Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations
Tampellini D, Magrané J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK.. The Journal of biological chemistry, 2007-04-27
Topic: Brain proteins, microglia and lab models
Plain-language summary
Immunotherapy against beta-amyloid peptide (Abeta) is a leading therapeutic direction for Alzheimer disease (AD). Experimental studies in transgenic mouse models of AD have demonstrated that Abeta immunization reduces Abeta plaque pathology and improves cognitive function. However, the biological mechanisms by which Abeta antibodies reduce amyloid accumulation in the brain remain unclear.
What this study adds
Evidence grade: Low
Treating Alzheimer's disease mutant cells or primary neurons with amyloid-beta antibodies decreased intracellular amyloid-beta levels. This is a laboratory cell study and does not demonstrate any treatment, cure, or prevention for Alzheimer's disease in people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tampellini, D., Magrané, J., Takahashi, R. H., Li, F., Lin, M. T., Almeida, C. G., et al. (2007). Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. The Journal of biological chemistry. https://doi.org/10.1074/jbc.m700373200
Vancouver
Tampellini D, Magrané J, Takahashi RH, Li F, Lin MT, Almeida CG, et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. The Journal of biological chemistry. 2007. doi:10.1074/jbc.m700373200. PMID: 17468102.
BibTeX
@article{tampellini2007-17468102,
author = {Tampellini, D. and Magrané, J. and Takahashi, R. H. and Li, F. and Lin, M. T. and Almeida, C. G. and Gouras, G. K.},
title = {{Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations}},
journal = {The Journal of biological chemistry},
year = {2007},
doi = {10.1074/jbc.m700373200},
pmid = {17468102},
url = {https://doi.org/10.1074/jbc.m700373200}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Experimental studies in transgenic mouse models of AD have demonstrated that Abeta immunization reduces Abeta plaque pathology and improves cognitive function.
- However, the biological mechanisms by which Abeta antibodies reduce amyloid accumulation in the brain remain unclear.
- We provide evidence that treatment of AD mutant neuroblastoma cells or primary neurons with Abeta antibodies decreases levels of intracellular Abeta.
- Antibody-mediated reduction in cellular Abeta appears to require that the antibody binds to the extracellular Abeta domain of the amyloid precursor protein (APP) and be internalized.
Why it matters
Treating Alzheimer's disease mutant cells or primary neurons with amyloid-beta antibodies decreased intracellular amyloid-beta levels. This is a laboratory cell study and does not demonstrate any treatment, cure, or prevention for Alzheimer's disease in people.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of biological chemistry) |
| Journal's citation record | 4 / 4 | Journal of Biological Chemistry: journal h-index 780 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2007 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 118 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.6 citations a year over 21 year(s) since 2007 |
| Impact for its field and year | 4 / 6 | Cited 9.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Gunnar K. Gouras: h-index 51 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Cornell University: institution h-index 1,649 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 17468102) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1074/jbc.m700373200
- PubMed: 17468102
- Original source →
- Free full text: Journal of Biological Chemistry →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Risk genes beyond APOE from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.